Joakim E Swedberg

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9213342/publications.pdf

Version: 2024-02-01

46	1,553	257357	315616
papers	citations	24 h-index	38 g-index

50	50	50	1615
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	An Ultrapotent and Selective Cyclic Peptide Inhibitor of Human Î²-Factor XIIa in a Cyclotide Scaffold. Journal of the American Chemical Society, 2021, 143, 18481-18489.	6.6	22
2	Binding Loop Substitutions in the Cyclic Peptide SFTI-1 Generate Potent and Selective Chymase Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 816-826.	2.9	13
3	Innentitelbild: Application and Structural Analysis of Triazoleâ€Bridged Disulfide Mimetics in Cyclic Peptides (Angew. Chem. 28/2020). Angewandte Chemie, 2020, 132, 11258-11258.	1.6	0
4	Application and Structural Analysis of Triazoleâ€Bridged Disulfide Mimetics in Cyclic Peptides. Angewandte Chemie - International Edition, 2020, 59, 11273-11277.	7.2	27
5	Application and Structural Analysis of Triazoleâ€Bridged Disulfide Mimetics in Cyclic Peptides. Angewandte Chemie, 2020, 132, 11369-11373.	1.6	7
6	Iterative Optimization of the Cyclic Peptide SFTI-1 Yields Potent Inhibitors of Neutrophil Proteinase 3. ACS Medicinal Chemistry Letters, 2019, 10, 1234-1239.	1.3	12
7	Potent, multi-target serine protease inhibition achieved by a simplified Î²-sheet motif. PLoS ONE, 2019, 14, e0210842.	1.1	7
8	KLK4 Inhibition by Cyclic and Acyclic Peptides: Structural and Dynamical Insights into Standard-Mechanism Protease Inhibitors. Biochemistry, 2019, 58, 2524-2533.	1.2	13
9	Rapid and Scalable Plant-Based Production of a Potent Plasmin Inhibitor Peptide. Frontiers in Plant Science, 2019, 10, 602.	1.7	24
10	Amino Acid Scanning at P5â€² within the Bowmanâ€“Birk Inhibitory Loop Reveals Specificity Trends for Diverse Serine Proteases. Journal of Medicinal Chemistry, 2019, 62, 3696-3706.	2.9	13
11	Characterising the Subsite Specificity of Urokinaseâ€Type Plasminogen Activator and Tissueâ€Type Plasminogen Activator using a Sequenceâ€Defined Peptide Aldehyde Library. ChemBioChem, 2019, 20, 46-50.	1.3	5
12	Highly Potent and Selective Plasmin Inhibitors Based on the Sunflower Trypsin Inhibitor-1 Scaffold Attenuate Fibrinolysis in Plasma. Journal of Medicinal Chemistry, 2019, 62, 552-560.	2.9	27
13	Conformational Flexibility Is a Determinant of Permeability for Cyclosporin. Journal of Physical Chemistry B, 2018, 122, 2261-2276.	1.2	104
14	Calcium-Mediated Allostery of the EGF Fold. ACS Chemical Biology, 2018, 13, 1659-1667.	1.6	10
15	Potent, Selective, and Cell-Penetrating Inhibitors of Kallikrein-Related Peptidase 4 Based on the Cyclic Peptide MCoTI-II. ACS Medicinal Chemistry Letters, 2018, 9, 1258-1262.	1.3	25
16	Engineering potent mesotrypsin inhibitors based on the plant-derived cyclic peptide, sunflower trypsin inhibitor-1. European Journal of Medicinal Chemistry, 2018, 155, 695-704.	2.6	20
17	Design of Potent and Selective Cathepsin G Inhibitors Based on the Sunflower Trypsin Inhibitor-1 Scaffold. Journal of Medicinal Chemistry, 2017, 60, 658-667.	2.9	48
18	Structural and functional characterization of chimeric cyclotides from the MÃ¶bius and trypsin inhibitor subfamilies. Biopolymers, 2017, 108, e22927.	1.2	11

#	Article	IF	Citations
19	Selective Substrates and Inhibitors for Kallikrein-Related Peptidase 7 (KLK7) Shed Light on KLK Proteolytic Activity in the Stratum Corneum. Journal of Investigative Dermatology, 2017, 137, 430-439.	0.3	50
20	Effects of linker sequence modifications on the structure, stability, and biological activity of a cyclic Î±â€conotoxin. Biopolymers, 2016, 106, 864-875.	1.2	10
21	Truncated Glucagon-like Peptide-1 and Exendin-4 Î±-Conotoxin pl14a Peptide Chimeras Maintain Potency and Î±-Helicity and Reveal Interactions Vital for cAMP Signaling in Vitro. Journal of Biological Chemistry, 2016, 291, 15778-15787.	1.6	10
22	Substrate-Guided Design of Selective FXIIa Inhibitors Based on the Plant-Derived Momordica cochinchinensis Trypsin Inhibitor-II (MCoTI-II) Scaffold. Journal of Medicinal Chemistry, 2016, 59, 7287-7292.	2.9	34
23	Diverse cyclic seed peptides in the Mexican zinnia (Zinnia haageana). Biopolymers, 2016, 106, 806-817.	1.2	13
24	Direct and indirect mechanisms of KLK4 inhibition revealed by structure and dynamics. Scientific Reports, 2016, 6, 35385.	1.6	28
25	Exploring the active site binding specificity of kallikrein-related peptidase 5 (KLK5) guides the design of new peptide substrates and inhibitors. Biological Chemistry, 2016, 397, 1237-1249.	1.2	28
26	Engineered protease inhibitors based on sunflower trypsin inhibitor-1 (SFTI-1) provide insights into the role of sequence and conformation in Laskowski mechanism inhibition. Biochemical Journal, 2015, 469, 243-253.	1.7	57
27	Effects of Cyclization on Peptide Backbone Dynamics. Journal of Physical Chemistry B, 2015, 119, 15821-15830.	1.2	36
28	Exploring experimental and computational markers of cyclic peptides: Charting islands of permeability. European Journal of Medicinal Chemistry, 2015, 97, 202-213.	2.6	76
29	Improving the Selectivity of Engineered Protease Inhibitors: Optimizing the P2 Prime Residue Using a Versatile Cyclic Peptide Library. Journal of Medicinal Chemistry, 2015, 58, 8257-8268.	2.9	51
30	Cyclic alpha-conotoxin peptidomimetic chimeras as potent GLP-1R agonists. European Journal of Medicinal Chemistry, 2015, 103, 175-184.	2.6	20
31	The Evolution ofMomordicaCyclic Peptides. Molecular Biology and Evolution, 2015, 32, 392-405.	3.5	26
32	Design and Synthesis of Truncated EGF-A Peptides that Restore LDL-R Recycling in the Presence of PCSK9 InÂVitro. Chemistry and Biology, 2014, 21, 284-294.	6.2	63
33	Translational Diffusion of Cyclic Peptides Measured Using Pulsed-Field Gradient NMR. Journal of Physical Chemistry B, 2014, 118, 11129-11136.	1.2	35
34	Disulfide-rich macrocyclic peptides as templates in drug design. European Journal of Medicinal Chemistry, 2014, 77, 248-257.	2.6	117
35	Mechanismâ€based selection of a potent kallikreinâ€related peptidase 7 inhibitor from a versatile library based on the sunflower trypsin inhibitor SFTIâ€1. Biopolymers, 2013, 100, 510-518.	1.2	38
36	Paclitaxel Resistance and Multicellular Spheroid Formation Are Induced by Kallikrein-Related Peptidase 4 in Serous Ovarian Cancer Cells in an Ascites Mimicking Microenvironment. PLoS ONE, 2013, 8, e57056.	1.1	47

#	Article	IF	Citations
37	Recent Progress Towards Pharmaceutical Applications of Disulfide-Rich Cyclic Peptides. Current Protein and Peptide Science, 2013, 14, 532-552.	0.7	25
38	Non-combinatorial library screening reveals subsite cooperativity and identifies new high-efficiency substrates for kallikrein-related peptidase 14. Biological Chemistry, 2012, 393, 331-341.	1.2	26
39	6 Natural, Engineered and Synthetic Inhibitors of Kallikrein-related Peptidases. , 2012, , 141-160.		1
40	Cyclotides as a basis for drug design. Expert Opinion on Drug Discovery, 2012, 7, 179-194.	2.5	102
41	Selective Cleavage of Human Sex Hormone-Binding Globulin by Kallikrein-Related Peptidases and Effects on Androgen Action in LNCaP Prostate Cancer Cells. Endocrinology, 2012, 153, 3179-3189.	1.4	11
42	Natural and Engineered Plasmin Inhibitors: Applications and Design Strategies. ChemBioChem, 2012, 13, 336-348.	1.3	19
43	Plasmin Substrate Binding Site Cooperativity Guides the Design of Potent Peptide Aldehyde Inhibitors. Biochemistry, 2011, 50, 8454-8462.	1.2	37
44	Mastering the Canonical Loop of Serine Protease Inhibitors: Enhancing Potency by Optimising the Internal Hydrogen Bond Network. PLoS ONE, 2011, 6, e19302.	1.1	61
45	Natural and engineered kallikrein inhibitors: an emerging pharmacopoeia. Biological Chemistry, 2010, 391, 357-74.	1.2	35
46	Substrate-Guided Design of a Potent and Selective Kallikrein-Related Peptidase Inhibitor for Kallikrein 4. Chemistry and Biology, 2009, 16, 633-643.	6.2	109